Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura.
Am J Ther
; 25(2): e270-e272, 2018.
Article
en En
| MEDLINE
| ID: mdl-29293474
The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Púrpura Trombocitopénica Idiopática
/
Inhibidores de Proteasoma
/
Bortezomib
Límite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Am J Ther
Asunto de la revista:
TERAPEUTICA
Año:
2018
Tipo del documento:
Article